Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114474 | 0.81 | CTNNB1 (0.53) | CTNNB1WNT3A | |
| SCHEMBL1065556 | 0.79 | PARP1 (0.66) | PARP1HCRTR1HCRTR2 | |
| SCHEMBL6680529 | 0.78 | PARP1 (0.46) | PARP1 | |
| SCHEMBL6680532 | 0.78 | PARP1 (0.46) | PARP1 | |
| SCHEMBL3360298 | 0.77 | PARP1 (0.72) | PARP1MAPK14HCRTR1HCRTR2MGLL | |
| SCHEMBL3455116 | 0.76 | HPGD (0.54) | PARP1HCRTR1HCRTR2 | |
| SCHEMBL15761166 | 0.75 | CTNNB1 (0.41) | CTNNB1WNT3A | |
| SCHEMBL8488477 | 0.75 | PARP1 (0.43) | PARP1HCRTR1HCRTR2 | |
| SCHEMBL1502069 | 0.75 | PARP1 (1.00) | PARP1HCRTR1HCRTR2MGLLRORC | |
| SCHEMBL729580 | 0.75 | PARP1 (0.74) | PARP1MAPK14HCRTR1HCRTR2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112010864-B | Vascular endothelial growth factor receptor inhibitor and preparation method and application thereof | 江苏威凯尔医药科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| WO-2019233458-A1 | VEGFR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019233458-A1 | VEGFR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8557848-B2 | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557848-B2 | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | PARP1 2312/4885MAPK14 3280/4885HCRTR1 716/4885 |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | PARP1 800/4885MAPK14 3566/4885HCRTR1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.